{"@context":["https://w3id.org/dats/context/sdo/dataset_sdo_context.jsonld","http://w3id.org/dats/context/obo/dataset_obo_context.jsonld"],"@type":"Project","acronym":"AMR Accelerator","description":"Antimicrobial Resistance Accelerator. Umbrella programme comprising the IMI projects AB-DIRECT, COMBINE, ERA4TB, GNA NOW, PRIMAVERA, RespiriNTM, RespiriTB, TRIC-TB and UNITE4TB","extraProperties":[{"@type":"CategoryValuesPair","category":"projectAcronym","values":[{"@context":"https://w3id.org/dats/context/sdo/annotation_sdo_context.jsonld","@type":"Annotation","value":"AMR Accelerator"}]}],"fundedBy":[{"@context":"https://w3id.org/dats/context/sdo/grant_sdo_context.jsonld","@type":"Grant","name":"IMI2 (Grant number )"}],"identifier":{"@context":"https://w3id.org/dats/context/sdo/identifier_info_sdo_context.jsonld","@type":"Identifier","identifier":"effc9746-5f11-11eb-917b-acde48001122"},"keywords":[{"@context":"https://w3id.org/dats/context/sdo/annotation_sdo_context.jsonld","@type":"Annotation","value":"IMI projects"},{"@context":"https://w3id.org/dats/context/sdo/annotation_sdo_context.jsonld","@type":"Annotation","value":"Antimicrobial resistance"},{"@context":"https://w3id.org/dats/context/sdo/annotation_sdo_context.jsonld","@type":"Annotation","value":"Infectious diseases"},{"@context":"https://w3id.org/dats/context/sdo/annotation_sdo_context.jsonld","@type":"Annotation","value":"AMR Accelerator"},{"@context":"https://w3id.org/dats/context/sdo/annotation_sdo_context.jsonld","@type":"Annotation","value":"Clinical trial design"},{"@context":"https://w3id.org/dats/context/sdo/annotation_sdo_context.jsonld","@type":"Annotation","value":"Conducting clinical trials"}],"projectAssets":[],"projectLeads":[],"title":"AMR Accelerator","types":[{"@context":"https://w3id.org/dats/context/sdo/annotation_sdo_context.jsonld","@type":"Annotation","value":"IMI projects"}]}